Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa vs. Geodon

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly claims long-term use of its atypical antipsychotic Zyprexa (olanzapine) yields greater efficacy than Pfizer's Geodon (ziprasidone), based on a 28-week, head-to-head study presented March 30 at the International Congress on Schizophrenia Research. The 548-patient, double-blind, flexible-dose study found long-term Zyprexa resulted in significantly better improvement for the study's primary endpoint, the Positive and Negative Syndrome Scale (p<0.001), and significantly more patients responded positively to treatment (58.6% vs. 42.5%). A study poster reports that "although [Zyprexa] patients had greater weight gain and elevated lipids, [Geodon] patients experienced significantly more adverse events," and a greater proportion of Geodon patients required a dose reduction due to side effects (26.9% vs. 14.8%
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002227

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel